Literature DB >> 27981308

Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: an Update on MR Imaging Findings with Recent Developments.

Jelena Djokić Kovač1, Marc-André Weber2.   

Abstract

Primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC) are the most common immune-mediated chronic cholestatic liver diseases leading to cirrhosis and liver failure. Although magnetic resonance imaging (MRI) is not a necessary procedure for the diagnosis of PBC, MRI is recommended for monitoring disease progression and early detection of complications. Even though liver cirrhosis subtypes have similar MR imaging features, there are some findings which could indicate PBC, such as the periportal halo sign. Additionally, MRI using diffusion-weighted imaging with apparent diffusion coefficient measurements provides non-invasive assessment of the stage of liver fibrosis. The role of cholangiography is crucial for the diagnosis of PSC. Since endoscopic retrograde cholangiography is an invasive procedure with occasional post-procedural complications, the latest guidelines suggest magnetic resonance cholangiography as a reference procedure for evaluation of patients suspected with PSC. Characteristic magnetic resonance cholangiography findings include multiple segmental strictures with slightly dilated ducts among them, usually on both intrahepatic and extrahepatic bile ducts. Furthermore, magnetic resonance cholangiography is useful in the follow-up of these patients, allowing for timely diagnosis of complications such as cholangiocellular carcinoma. With the exception of ursodeoxycholic acid, which slows the progression of PBC, the only curative treatment for both PSC and PBC is still liver transplantation. However, recurrent disease occurs in some patients indicating the need for development of new more effective therapies.

Entities:  

Mesh:

Year:  2016        PMID: 27981308     DOI: 10.15403/jgld.2014.1121.254.vac

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  7 in total

1.  [Radiologic diagnosis of the gallbladder and bile ducts - part 2 : Acute and chronic cholecystitis, primary sclerosing cholangitis (PSC), benign and malignant masses of the biliary system].

Authors:  H Helmberger; B Kammer
Journal:  Radiologe       Date:  2018-12       Impact factor: 0.635

Review 2.  Noninvasive imaging of hepatic dysfunction: A state-of-the-art review.

Authors:  Ting Duan; Han-Yu Jiang; Wen-Wu Ling; Bin Song
Journal:  World J Gastroenterol       Date:  2022-04-28       Impact factor: 5.374

3.  Prospective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis.

Authors:  S Keller; J Sedlacik; T Schuler; R Buchert; M Avanesov; R Zenouzi; A W Lohse; H Kooijman; J Fiehler; C Schramm; J Yamamura
Journal:  Eur Radiol       Date:  2018-07-16       Impact factor: 5.315

4.  Comparison of liver stiffness measurement with MRE and liver and spleen volumetry for prediction of disease severity and hepatic decompensation in patients with primary sclerosing cholangitis.

Authors:  Ilkay S Idilman; Hsien Min Low; Zeinab Bakhshi; John Eaton; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2020-03

Review 5.  Etiological classification and treatment strategies for secondary bile duct dilatation.

Authors:  Yunfu Lv; Ning Liu; Hongfei Wu; Zhuori Li
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-09

Review 6.  Cholangitis: Diagnosis, Treatment and Prognosis.

Authors:  Amir Houshang Mohammad Alizadeh
Journal:  J Clin Transl Hepatol       Date:  2017-09-07

7.  Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group.

Authors:  Sudhakar K Venkatesh; Christopher L Welle; Frank H Miller; Kartik Jhaveri; Kristina I Ringe; John E Eaton; Helen Bungay; Lionel Arrivé; Ahmed Ba-Ssalamah; Aristeidis Grigoriadis; Christoph Schramm; Ann S Fulcher
Journal:  Eur Radiol       Date:  2021-08-06       Impact factor: 5.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.